|
OALib Journal期刊
ISSN: 2333-9721
费用：99美元
|
|
|
|
先导化合物结构优化策略（三）——通过化学修饰改善水溶性
, PP. 1238-1247
Keywords: 水溶性,结构修饰,前药,先导化合物优化
Abstract:
水溶性是有机小分子药物极为重要的物理化学性质，也是小分子药物研发过程中的关键问题之一。良好的水溶性有助于药效的发挥和药代动力学性质的改善。在药物化学领域，通过化学结构修饰方法改善药物的水溶性，是从溶解的本质上考虑和解决问题的基本方法。本文综述了通过化学结构修饰改善水溶性的基本策略，包括成盐修饰、引入极性基团、降低脂溶性、构象优化、前药修饰等。
| [1] | liuh,wangj,lind,etal.leadcompoundoptimizationstrategy(2)-structureoptimizationstrategyforreducingtoxicityrisksindrugdesign[j].actapharmsin(药学学报),2014,49:1-15.
|
| [2] | wangj,liuh.leadcompoundoptimizationstrategy(1)-changingmetabolicpathwaysandoptimizingmetabolismstability[j].actapharmsin(药学学报),2013,48:1521-1531.
|
| [3] | shenf,suq,zhouw.researchanddevelopmentofpharmaceuticalsalts[j].progpharmsci,2012,36:151-157.
|
| [4] | bhattacharsn,deschenesla,wesleyja.solubility:it'snotjustforphysicalchemists[j].drugdiscovtoday,2006,11:1012-1018.
|
| [5] | ishikawam,hashimotoy.improvementinaqueoussolubilityinsmallmoleculedrugdiscoveryprogramsbydisruptionofmolecularplanarityandsymmetry[j].jmedchem,2011,54:1539-1554.
|
| [6] | bastinrj,bowkermj,slaterbj.saltselectionandoptimizationproceduresforpharmaceuticalnewchemicalentities[j].orgprocresdev,2000,4:427-435.
|
| [7] | niemanja,heasleyse,nairsk,etal.medi225-modificationsofc-2onthepyrroloquinolinetemplateaimedatthedevelopmentofpotentherpesvirusantivirals[c].the232ndacsnationalmeeting,sanfrancisco,ca,september10-14,2006.
|
| [8] | niemanja,nairsk,heasleyse,etal.modificationsofc-2onthepyrroloquinolinetemplateaimedatthedevelopmentofpotentherpesvirusantiviralswithimprovedaqueoussolubility[j].bioorgmedchemlett,2010,20:3039-3042.
|
| [9] | scottjs,bircham,brocklehurstkj,etal.useofsmall-moleculecrystalstructurestoaddresssolubilityinanovelseriesofgproteincoupledreceptor119agonists:optimizationofaleadandinvivoevaluation[j].jmedchem,2012,55:5361-5379.
|
| [10] | scottjs,bircham,brocklehurstkj,etal.optimizationofaqueoussolubilityinaseriesofgproteincoupledreceptor119(gpr119)agonists[j].medchemcomm,2013,4:95-100.
|
| [11] | ohashit,oguroy,tanakat,etal.discoveryoftheinvestigationaldrugtak-441,apyrrolo[3,2-c]pyridinederivative,asahighlypotentandorallyactivehedgehogsignalinginhibitor:modificationofthecoreskeletonforimprovedsolubility[j].bioorgmedchem,2012,20:5507-5517.
|
| [12] | rautioj,kumpulainenh,heimbacht,etal.prodrugs:designandclinicalapplications[j].natrevdrugdiscov,2008,7:255-270.
|
| [13] | jix,wangj,zhangl,etal.applicationofphosphatesandphosphonatesprodrugsindrugresearchanddevelopment[j].actapharmsin(药学学报),2013,48:621-634.
|
| [14] | furfinees,bakerct,halemr,etal.preclinicalpharmacologyandpharmacokineticsofgw433908,awater-solubleprodrugofthehumanimmunodeficiencyvirusproteaseinhibitoramprenavir[j].antimicrobagentschemother,2004,48:791-798.
|
| [15] | xinqs,fanhx,guob,etal.design,synthesis,andstructure-activityrelationshipstudiesofhighlypotentnovelbenzoxazinyl-oxazolidinoneantibacterialagents[j].jmedchem,2011,54:7493-7502.
|
| [16] | oreillys,rowinskyek.theclinicalstatusofirinotecan(cpt-11),anovelwatersolublecamptothecinanalogue:1996[j].critrevoncolhematol,1996,24:47-70.
|
| [17] | greenwaldrb,gilbertcw,pendria,etal.drugdeliverysystems:watersolubletaxol2'-poly(ethyleneglycol)esterprodrugs-designandinvivoeffectiveness[j].jmedchem,1996,39:424-431.
|
| [18] | bhattrl,devriesp,tulinskyj,etal.synthesisandinvivoantitumoractivityofpoly(l-glutamicacid)conjugatesof20(s)-camptothecin[j].jmedchem,2003,46:190-193.
|
| [19] | daviesnm,watsonms.clinicalpharmacokineticsofsulindac-adynamicolddrug[j].clinpharmacokinet,1997,32:437-459.
|
| [20] | hemenwayrn,nti-addaek,guarinovr,etal.preparation,characterizationandinvivoconversionofnewwater-solublesulfenamideprodrugsofcarbamazepine[j].bioorgmedchemlett,2007,17:6629-6632.
|
| [21] | bollinim,cisnerosja,spasovka,etal.optimizationofdiarylazinesasanti-hivagentswithdramaticallyenhancedsolubility[j].bioorgmedchemlett,2013,23:5213-5216.
|
| [22] | guozr.strategyofmoleculardesignofdrugs:theunificationofmacro-propertiesandmicro-structuresofamolecule[j].actapharmsin(药学学报),2008,43:227-233.
|
| [23] | ranyq,yalkowskysh.predictionofdrugsolubilitybythegeneralsolubilityequation(gse)[j].jcheminfcomputsci,2001,41:354-357.
|
| [24] | veberdf,johnsonsr,chenghy,etal.molecularpropertiesthatinfluencetheoralbioavailabilityofdrugcandidates[j].jmedchem,2002,45:2615-2623.
|
| [25] | paulekuhngs,dressmanjb,saalc.trendsinactivepharmaceuticalingredientsaltselectionbasedonanalysisoftheorangebookdatabase[j].jmedchem,2007,50:6665-6672.
|
| [26] | lamkw,xujj,ngkm.pharmaceuticalsaltformationguidedbyphasediagrams[j].indengchemres,2010,49:12503-12512.
|
| [27] | zhangdp,luwg.saltscreeningindrugdevelopmentprocess[j].chinjpharm(中国医药工业杂志),2011,42:631-635.
|
| [28] | guerrierip,jarringk,taylorls.impactofcounteriononthechemicalstabilityofcrystallinesaltsofprocaine[j].jpharmsci,2010,99:3719-3730.
|
| [29] | wangj,liuh.applicationofnitrileindrugdesign[j].chinjorgchem(有机化学),2012,32:1643-1652.
|
| [30] | huntjt,dingcz,batorskyr,etal.discoveryof(r)-7-cyano-2,3,4,5-tetrahydro-1-(1h-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1h-1,4-benzodiazepine(bms-214662),afarnesyltransferaseinhibitorwithpotentpreclinicalantitumoractivity[j].jmedchem,2000,43:3587-3595.
|
| [31] | ballardsa,turnerla,nayloram.sildenafil,apotentselectiveinhibitoroftype5phosphodiesterase,enhancesnitricoxide-dependentrelaxationofrabbitcorpuscavernosum[j].brjpharmacol,1996,118:153-153.
|
| [32] | ohashit,oguroy,tanakat,etal.discoveryofpyrrolo[3,2-c]quinoline-4-onederivativesasnovelhedgehogsignalinginhibitors[j].bioorgmedchem,2012,20:5496-5506.
|
| [33] | pressnj,taylorrj,fullertonjd,etal.solubility-drivenoptimizationofphosphodiesterase-4inhibitorsleadingtoaclinicalcandidate[j].jmedchem,2012,55:7472-7479.
|
| [34] | kasugaj,ishikawam,yoneharam,etal.improvementofwater-solubilityofbiarylcarboxylicacidperoxisomeproliferator-activatedreceptor(ppar)δ-selectivepartialagonistsbydisruptionofmolecularplanarity/symmetry[j].bioorgmedchem,2010,18:7164-7173.
|
| [35] | liq,chudtw,claibornea,etal.synthesisandstructure-activityrelationshipsof2-pyridones:anovelseriesofpotentdnagyraseinhibitorsasantibacterialagents[j].jmedchem,1996,39:3070-3088.
|
| [36] | fraymj,bulldj,carrcl,etal.structure-activityrelationshipsof1,4-dihydro-(1h,4h)-quinoxaline-2,3-dionesasn-methyl-d-aspartate(glycinesite)receptorantagonists.1.heterocyclicsubstituted5-alkylderivatives[j].jmedchem,2001,44:1951-1962.
|
| [37] | vollmannk,qurishir,hockemeyerj,etal.synthesisandpropertiesofanewwater-solubleprodrugoftheadenosinea(2a)receptorantagonistmsx-2[j].molecules,2008,13:348-359.
|
| [38] | fuxz,zhangw,wangy,etal.design,synthesisandanti-oxidativeevaluationofl-aminoacidprodrugsofscutellarein[j].actapharmsin(药学学报),2011,46:548-555.
|
| [39] | rodriguez-perezt,fernandezs,sanghviys,etal.chemoenzymaticsynthesesandanti-hiv-1activityofglucose-nucleosideconjugatesasprodrugs[j].bioconjugchem,2010,21:2239-2249.
|
| [40] | linys,tungpraditr,sinchaikuls,etal.targetingthedeliveryofglycan-basedpaclitaxelprodrugstocancercellsviaglucosetransporters[j].jmedchem,2008,51:7428-7441.
|
| [41] | vignarolig,zamperinic,dreassie,etal.pyrazolo[3,4-d]pyrimidineprodrugs:strategicoptimizationoftheaqueoussolubilityofdualsrc/ablinhibitors[j].acsmedchemlett,2013,4:57-61.
|
Full-Text
|
|
Contact Us
service@oalib.com QQ:3279437679 
WhatsApp +8615387084133
|
|
